Martine
Martine Aiach, Sevres FR
Patent application number | Description | Published |
---|---|---|
20090053693 | Identification of polymorphisms in the epcr gene associated with thrombotic risk - The invention relates to an in vitro method for determining the risk of developing thrombosis in a subject, which method involves identifying a particular haplotype EPCR gene. | 02-26-2009 |
Martine Artiaga, Paris FR
Patent application number | Description | Published |
---|---|---|
20140343061 | 1,3,5 -Triazine-2-Amine Derivatives, Preparation Thereof And Diagnostic And Therapeutic Use Thereof - The present invention relates to compounds corresponding to formula (I) in which: —R | 11-20-2014 |
Martine Bagot, Paris FR
Patent application number | Description | Published |
---|---|---|
20080274468 | NOVEL MEANS FOR THE DIAGNOSIS AND THERAPY OF CTCL - The invention relates to a novel molecule, termed SC5 by the inventors, to a novel allelic form of p140, and to the biological applications of SC5 and p140 molecules, notably in the diagnosis and therapy of CTCL. | 11-06-2008 |
20110151472 | NOVEL MEANS FOR THE DIAGNOSIS AND THERAPY OF CTCL - The invention relates to a novel molecule, termed SC5 by the inventors, to a novel allelic form of p140, and to the biological applications of SC5 and p140 molecules, notably in the diagnosis and therapy of CTCL. | 06-23-2011 |
20120329063 | NOVEL MEANS FOR THE DIAGNOSIS AND THERAPY OF CTCL - The invention relates to a novel molecule, termed SC5 by the inventors, to a novel allelic form of p140, and to the biological applications of SC5 and p140 molecules, notably in the diagnosis and therapy of CTCL. | 12-27-2012 |
Martine Bagot, Cedex 10 Paris FR
Patent application number | Description | Published |
---|---|---|
20120288499 | METHODS FOR DIAGNOSIS AND TREATMENT OF CUTANEOUS T CELL LYMPHOMAS - The present invention relates to a method for diagnosing a cutaneous T cell lymphoma (CTCL) in a patient, detecting the abnormal expression of NKp46 receptor on malignant T cells and to a kit for diagnosing a CTCL in a patient, said kit comprising an antibody capable of detecting NKp46 receptor and an antibody capable of detecting T cells. Furthermore, the invention refers to an anti-NKp46 antibody for use in the treatment of CTCL and a pharmaceutical composition for the treatment of CTCL comprising said anti-NKp46 antibody. | 11-15-2012 |
Martine Barkats, Charenton Le Pont FR
Patent application number | Description | Published |
---|---|---|
20100130594 | CNS GENE DELIVERY USING PERIPHERAL ADMINISTRATION OF AAV VECTORS - The present invention relates to compositions and methods for the delivery of therapeutic proteins to the CNS using recombinant AAV vectors. More specifically, the invention relates to compositions and methods for delivering proteins into the cerebrospinal fluid of mammalian subjects through peripheral administration of AAV vectors. The invention may be used to treat various disorders of the central nervous system, including degenerative diseases and motor neuron diseases. | 05-27-2010 |
20100240739 | WIDESPREAD GENE DELIVERY TO MOTOR NEURONS USING PERIPHERAL INJECTION OF AAV VECTORS - The present invention relates to compositions and methods, in particular to methods based on systemic injection of rAAV, for delivering genes to cells of the central nervous system in mammals, such as brain neurons or glial cells, and in particular to motor neurons or glial cells of the spinal cord The invention also relates to methods of treating motor neuron disorders in mammals by expression of therapeutic genes. The invention stems from the unexpected discovery that peripheral injection of AAV vectors leads to a bypass of the blood brain barrier and a massive infection of motor neurons. The invention may be used in any mammal, including human subjects. | 09-23-2010 |
20120141422 | WIDESPREAD GENE DELIVERY TO THE RETINA USING SYSTEMIC ADMINISTRATION OF AAV VECTORS - The present invention relates to compositions and methods, in particular to methods based on systemic administration of scAAV, for delivering genes to cells of the retina of mammals, and in particular to photoreceptor cells, ganglion cells, glial cells, inner nuclear layer cells or cells of the retinal pigmented epithelium. | 06-07-2012 |
20150182637 | WIDESPREAD GENE DELIVERY OF GENE THERAPY VECTORS - The present invention relates to improved compositions and methods for delivering and expressing therapeutic genes in mammals. More particularly, the invention stems from the unexpected discovery that a remarkable, massive and widespread therapeutic gene delivery and expression is obtained in mammals when a therapeutic gene is incorporated in a viral vector and administered both into the CSF and into the blood of the mammal. Such a combined administration leads to a surprising and substantial therapeutic benefit in the mammal as compared to administration in one single site, and further enables the use of reduced doses of the virus. The invention may be used in any mammal, including human subjects, and is particularly suited to treat multi-systemic diseases, such as motor neuron or lysosomal disorders, where widespread expression of a therapeutic gene is desirable. | 07-02-2015 |
Martine Bayssas, Lausanne CH
Patent application number | Description | Published |
---|---|---|
20110189204 | Treatment of Disease with Proteasone Inhibitors - A method is provided for treating cancer in a patient comprising administering to said patient a proteasome inhibitor at least three days a week. | 08-04-2011 |
Martine Bouclier, Valbonne FR
Patent application number | Description | Published |
---|---|---|
20150119825 | OPTIMIZING UNGUAL TREATMENT BY QUANTITATIVE AUTORADIOGRAPHY - A method is described for optimizing ungual treatment. The method can include (a) providing a nail having at least two spaced apart holes formed from a surface thereof and extending into the nail, and (b) topically applying a radiolabeled pharmaceutical composition to the nail. At least a portion of the composition is received in the at least two holes. The method also includes (c) sectioning a portion of the nail proximate the at least two holes into a plurality of sections, (d) determining, for each of the plurality of sections, a concentration of radioactivity in the section as a function of position with respect to the at least two holes, and (e) optimizing a spacing between the at least two holes based at least partially on the determinations in step (d). A method of ungual treatment using the optimized spacing is also described. | 04-30-2015 |
Martine Bujoli-Doeuff, Suce Sur Erdre FR
Patent application number | Description | Published |
---|---|---|
20100216990 | NOVEL PHOTOCHROMIC MATERIALS - The invention relates to hybrid organic-inorganic materials containing molybdenum and having photochromic properties. The invention also relates to the use thereof, particularly in cosmetics and in the glass industry, e.g. in glazing applications or in the production of ocular glasses. | 08-26-2010 |
Martine Burtin, Paris FR
Patent application number | Description | Published |
---|---|---|
20140079769 | METHODS FOR PREDICTING THE PROGRESSION AND TREATING A CHRONIC KIDNEY DISEASE IN A PATIENT - The present invention relates to a method for predicting the progression of chronic kidney disease (CKD) in a patient and also to an inhibitor of NGAL gene expression or an NGAL antagonist for use in the prevention or the treatment of CKD. | 03-20-2014 |
Martine Cao, West Lebanon, NH US
Patent application number | Description | Published |
---|---|---|
20150225352 | CDDO-ME AMINO ACID CONJUGATES AND METHODS OF USE - 2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid amino acid derivatives having antiinflammatory properties are provided. Pharmaceutical compositions and methods for preventing or treating inflammation or a disease or condition mediated by inflammation are described. | 08-13-2015 |
Martine Cazales, Balma FR
Patent application number | Description | Published |
---|---|---|
20080219987 | Novel Phosphorylated Phosphatase Cdc25b Sequences, Antibodies Directed Against Said Sequences and Uses Thereof - A peptide sequence includes a fragment of at least 10 amino acids derived from the following SEQ ID NO:1: DRKMEVEELS | 09-11-2008 |
Martine Clarisse, Lys-Lez-Lannoy FR
Patent application number | Description | Published |
---|---|---|
20140287485 | PRODUCT AND METHOD FOR THE REMOVAL OF BIOFILMS - Composition for the removal of biofilms present on a substrate, characterized in that it comprises at least one detergent component comprising a sequestrant and also a wetting agent and a dispersant and at least one enzymatic component containing at least one protease, at least one laccase and at least one polysaccharidase, method of implementation thereof and uses thereof. | 09-25-2014 |
Martine Clozel, Binnigen CH
Patent application number | Description | Published |
---|---|---|
20130005734 | THERAPEUTIC COMPOSITIONS - The invention relates to a product containing the compound of formula (I) below (I) or a pharmaceutically acceptable salt of this compound, in combination with at least one compound having PDE5-inhibitory properties, or a pharmaceutically acceptable salt thereof, for therapeutic use, simultaneously, separately or over a period of time, in the treatment of a disease wherein vasoconstriction is involved. | 01-03-2013 |
20130210830 | THERAPEUTIC COMPOSITIONS - The invention relates to a product containing the compound of formula (I) below (I) or a pharmaceutically acceptable salt of this compound, in combination with at least one compound having PDE5-inhibitory properties, or a pharmaceutically acceptable salt thereof, for therapeutic use, simultaneously, separately or over a period of time, in the treatment of a disease wherein vasoconstriction is involved. | 08-15-2013 |
20140148460 | THERAPEUTIC COMPOSITIONS - The invention relates to a product containing the compound of formula (I) below (I) or a pharmaceutically acceptable salt of this compound, in combination with at least one compound having PDE5-inhibitory properties, or a pharmaceutically acceptable salt thereof, for therapeutic use, simultaneously, separately or over a period of time, in the treatment of a disease wherein vasoconstriction is involved. | 05-29-2014 |
Martine Clozel, Binningen CH
Patent application number | Description | Published |
---|---|---|
20090318459 | Therapeutic Compositions Comprising a Specific Endothelin Receptor Antagonist and a PDE5 Inhibitor - The invention relates to a product containing the compound of formula (I) below | 12-24-2009 |
20100022568 | ENDOTHELIN RECEPTOR ANTAGONISTS FOR EARLY STAGE IDIOPATHIC PULMONARY FIBROSIS - This present invention relates to the use of an endothelin receptor antagonist for the preparation of a medicament for the treatment of early stage idiopathic pulmonary fibrosis. | 01-28-2010 |
20100311774 | Combination Comprising Paclitaxel for Treating Ovarian Cancer - The invention relates to the combination of an endothelin receptor antagonist of formula (I) with paclitaxel, and in particular to this combination for therapeutic use, simultaneously, separately or over a period of time, in the treatment of ovarian cancer. | 12-09-2010 |
20110136818 | THERAPEUTIC COMPOSITIONS CONTAINING MACITENTAN - The invention relates to a product containing the compound of formula (I) below or a pharmaceutically acceptable salt of this compound, in combination with at least one compound having prostacyclin receptor (IP) agonist properties, or a pharmaceutically acceptable salt thereof. | 06-09-2011 |
20130317048 | COMBINATION COMPRISING PACLITAXEL FOR TREATING OVARIAN CANCER - The invention relates to the combination of an endothelin receptor antagonist of formula (I) | 11-28-2013 |
20140329824 | THERAPEUTIC COMPOSITIONS CONTAINING MACITENTAN - The invention relates to a product containing the compound of formula (I) below or a pharmaceutically acceptable salt of this compound, in combination of at least one compound having prostacyclin receptor (IP) agonist properties, or a pharmaceutically acceptable salt thereof | 11-06-2014 |
Martine Croisy, Cernay La Ville FR
Patent application number | Description | Published |
---|---|---|
20080242704 | Substituted Oxazole Derivatives and their Use as Tyrosine Kinase Inhibitors - The present invention relates to novel compounds selected from substituted oxazole derivatives of formula (I) that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective c-kit, bcr-abl and Fit-3 inhibitors. | 10-02-2008 |
20100113471 | 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors - The present invention relates to novel compounds selected from 2-aminoaryloxazoles that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic and degenerative disorders. More particularly, these compounds are potent and selective c-kit, bcr-abl, FGFR3 and/or Flt-3 inhibitors. | 05-06-2010 |
20120108616 | SUBSTITUTED OXAZOLE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS - The present invention relates to novel compounds selected from substituted oxazole derivatives of formula (I) that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective c-kit, bcr-abl and Flt-3 inhibitors. | 05-03-2012 |
Martine Daenzer-Alloncle, Les Hopitaux Neufs FR
Patent application number | Description | Published |
---|---|---|
20150118380 | COMPOSITION FOR PREPARATION OF A FOOD OR BEVERAGE PRODUCT - The present invention relates to a composition for preparation of a food or beverage product. The composition comprises a foamer ingredient releasing gas upon dissolution in aqueous liquid; and a beverage or foodstuff ingredient comprising particles of ground vegetable material in a matrix comprising a vegetable extract; wherein the beverage or foodstuff ingredient has a retarded solubility such that a foam has been formed by the foamer ingredient, before the beverage or foodstuffs ingredient has dissolved, when the composition is dissolved in an aqueous liquid to produce a food or beverage product. | 04-30-2015 |
Martine Delchambre, King Of Prussia, PA US
Patent application number | Description | Published |
---|---|---|
20100184836 | VACCINE - This invention relates to novel HIV polypeptide and polynucleotide fusions of Gag, Pol and Nef which are useful in immunogenic compositions and vaccines. The invention relates in particular to a polypeptide which comprises Nef or an immunogenic fragment thereof, and p17 Gag and/or p24 Gag or immunogenic fragments thereof, wherein when both p17 and p24 Gag are present there is at least one HIV antigen or immunogenic fragment between them. The polypeptide may also comprise Pol or RT or an immunogenic fragment thereof. | 07-22-2010 |
Martine Denicourt, Ste-Cecile De Milton CA
Patent application number | Description | Published |
---|---|---|
20090211147 | ANIMAL EUTHANASIA BY ELECTROCUTION - Apparatus for euthanasia of animals by electrocution includes a container on wheels formed of an electrically insulating material and a rechargeable 12V battery powered control unit carried on the container for supplying through a transformer AC electric current at 110V to electrodes through insulated electrical supply cables. The first electrode is a conductive wire forming a loop arranged to be wrapped around the snout and through the mouth of the animal. The second electrode is a belt shaped and arranged to wrap around the belly of the animal at a position just in front of the rear legs. An alternative second electrode may be a rectal probe. Each of the electrodes is attached to a winch by which it can be pulled to apply tension electrode during the electrocution. In a second arrangement the control unit and the electrodes are arranged to be hand carried to the animal. | 08-27-2009 |
Martine Dhedin, Sain Bel FR
Patent application number | Description | Published |
---|---|---|
20110129871 | CULTURE MEDIUM ENABLING STAPHYLOCOCCUS AUREUS TO BE DIFFERENTIATED FROM COAGULASE-NEGATIVE STAPHYLOCOCCI - A specific culture medium for growth, detection, identification and/or counting of | 06-02-2011 |
Martine Doisy, Plascassier FR
Patent application number | Description | Published |
---|---|---|
20100039650 | Physical Value Sensor Comprising An Optical Fiber That Is Not Sensitive To Static Values - The subject of the present invention is a dynamic sensor of physical quantities with optical waveguide with optically-pumped amplifier medium, which requires no interferometer or reference sensor and which makes it possible to obtain at least the same level of performance, in terms of sensitivity, as known sensors of this type, and this waveguide is linked at one end to a selective mirror, and comprises at its other end an interrogation laser, the reflection of which on the selective mirror produces a wave which, by interference with the incident wave, provokes the periodic saturation of the gain of the waveguide. | 02-18-2010 |
20110019179 | Self-Referenced Optical Fiber Sensor and Related Sensor Network - The general field of the invention is that of fiber-optic sensors comprising at least one measurement optical fiber having an optically pumped doped amplifying medium, the optical characteristics of which are sensitive to a physical quantity, the fiber having at least one Bragg grating. The fiber is designed so as to generate, in the amplifying medium, two optical waves having different optical frequencies that propagate in the same direction after reflection on the Bragg grating and are emitted by the amplifying medium, the two optical frequencies depending on the physical quantity. The two waves may be generated using either a birefringent polarization-maintaining fiber or a DBR (Distributed Bragg Reflector) laser cavity. Notably, this sensor may be used as a hydrophone. | 01-27-2011 |
20110122417 | Self-Referenced Optical Fiber Sensor with Stimulated Brillouin Scattering - A sensor is used to measure a physical quantity and includes at least: a measurement optical fiber including at least one Bragg grating; optical means designed to inject, into the fiber, a first, “pump” wave at a first optical frequency and a second, “probe” wave at a second optical frequency, the second optical frequency being different from the first optical frequency, the Bragg grating being designed to reflect the first and second optical waves, and the optical power of the first wave being sufficient to give, after interaction with the second wave reflected by stimulated Brillouin scattering, a “Stokes” wave, the frequency of which is representative of the physical quantity to be measured; and means for analyzing the difference in frequency between the two, “pump” and “Stokes”, optical waves. The sensor may notably be used as a hydrophone. | 05-26-2011 |
20140036635 | ALL-OPTICAL HYDROPHONE INSENSITIVE TO TEMPERATURE AND TO STATIC PRESSURE - The invention consists of an optical hydrophone, an optical fiber element forming a laser cavity, housed in a mechanical structure which comprises an open cylindrical rigid body, defining the cavity enclosing a fluid and in which the optical fiber element is housed, and closed at its ends by two end caps which keep the optical fiber element permanently under tension, in a longitudinal rectilinear position inside the cavity. The end caps are configured in such a way that when the exterior pressure varies, they undergo a deformation giving rise to a variation in the length of the optical fiber element and that when the temperature varies, they undergo a deformation giving rise to a variation in the length of the optical fiber element which compensates for that induced on this element by the temperature variation. The mechanical structure furthermore exhibits one or more orifices allowing equilibration of the static pressures. | 02-06-2014 |
Martine El-Etr, Paris FR
Patent application number | Description | Published |
---|---|---|
20120231052 | NEUROPROTECTION AND MYELIN REPAIR USING NESTORONE.RTM. - Methods for treating neurodegeneration and/or myelination in patients are disclosed comprising treating the patient with a progestin compound which exerts binding to progesterone receptors and elicits progesterone-receptor-induced biological responses without interacting with the androgen receptor and without inducing androgen or glucocorticoid biological responses at a dosage sufficient to prevent or reduce neurodegeneration. The progestin compound preferably comprises 16-methylene-17α-acetoxy-19-norpregn-4-ene-3,20-dione, and the methods include combining the progestin compound with an estrogen compound to provide both contraception and treatment for myelin repair and neurodegeneration. | 09-13-2012 |
20130116217 | NEUROPROTECTION AND MYELIN REPAIR USING NESTORONE.RTM. - Methods for treating neurodegeneration and/or myelination in patients are disclosed comprising treating the patient with a progestin compound which exerts binding to progesterone receptors and elicits progesterone-receptor-induced biological responses without interacting with the androgen receptor and without inducing androgen or glucocorticoid biological responses at a dosage sufficient to prevent or reduce neurodegeneration. The progestin compound preferably comprises 16-methylene-17α-acetoxy-19-norpregn-4-ene-3,20-dione, and the methods include combining the progestin compound with an estrogen compound to provide both contraception and treatment for myelin repair and neurodegeneration, and include effects on stroke and TBI. | 05-09-2013 |
Martine Fouchereau-Peron, Tregunc FR
Patent application number | Description | Published |
---|---|---|
20110039768 | FISH PROTEIN HYDROLYSATE HAVING A SATIETOGENIC ACTIVITY, NUTRACEUTICAL AND PHARMACOLOGICAL COMPOSITIONS COMPRISING SUCH A HYDROLYSATE AND METHOD FOR OBTAINING SAME, - The present invention relates to a fish protein hydrolysate containing molecules capable of exerting a satietogenic activity and of regulating food intake in humans or animals. More specifically, the protein hydrolysate according to the invention enables stimulation of the secretion of endogenous cholescystokinins (CCKs) and of endogenous glucagon-like peptide 1 (GLP1) molecules by intestinal cells and the supply of exogenous CCKs. The fish protein hydrolysate according to the invention is obtained by enzymatic hydrolysis of at least one protein source selected from the group composed of the pelagic fish species | 02-17-2011 |
20150025001 | FISH PROTEIN HYDROLYSATE HAVING A SATIETOGENIC ACTIVITY, NUTRACEUTICAL AND PHARMACOLOGICAL COMPOSITIONS COMPRISING SUCH A HYDROLYSATE AND METHOD FOR OBTAINING SAME - The present invention relates to a fish protein hydrolysate containing molecules capable of exerting a satietogenic activity and of regulating food intake in humans or animals. More specifically, the protein hydrolysate according to the invention enables stimulation of the secretion of endogenous cholescystokinins (CCKs) and of endogenous glucagon-like peptide 1 (GLP1) molecules by intestinal cells and the supply of exogenous CCKs. The fish protein hydrolysate according to the invention is obtained by enzymatic hydrolysis of at least one protein source selected from the group composed of the pelagic fish species | 01-22-2015 |
Martine Gilleron, Auzeville Tolosane FR
Patent application number | Description | Published |
---|---|---|
20100048492 | COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF DISEASES ASSOCIATED WITH TNF AND/OR IL-12 OVEREXPRESSION - The present invention relates to a pharmaceutical composition comprising at least one compound of formula (I): | 02-25-2010 |
20100166801 | SULFOGLYCOLIPID ANTIGENS, THEIR PROCESS OF PREPARATION, AND THEIR USE AGAINST TUBERCULOSIS - The present invention relates to compounds of the following general formula (I) their process of preparation and their use in the treatment or the prophylaxis of tuberculosis. | 07-01-2010 |
20100255015 | PHARMACEUTICALS COMPOSITIONS COMPRISING ACTINOMYCETE GLYCEROL ACYL DERIVATIVES ANTIGENS, THEIR PROCESS OF EXTRACTION, AND THEIR USE AGAINST TUBERCULOSIS - The present invention relates to the therapeutic use of actinomycete glycerol monomycolate derivatives as antigens, their process of extraction, and their use in the treatment or the prophylaxis of tuberculosis. | 10-07-2010 |
Martine Giret, Gagny FR
Patent application number | Description | Published |
---|---|---|
20110222138 | ELECTRICALLY CONTROLLABLE DEVICE HAVING IMPROVED TRANSPORTATION OF THE ELECTRIC CHARGES OF THE ELECTROACTIVE MEDIUM - This device comprises the following stack of layers: a first substrate having a glass function (V | 09-15-2011 |
Martine Grornrnfijk, Barendrecht NL
Patent application number | Description | Published |
---|---|---|
20150327586 | Non-Medical Increase or Maintenance of Body Weight of a Mammal - Non-medical use of at least two components selected from the group of: (i) nucleoside equivalents, (ii) n-3 polyunsaturated fatty acids selected from the group of DHA, DPA and EPA, (iii) vitamins B, (iv) phospholipids, (v) antioxidants and (vi) cholines—with the proviso that at least one (i) nucleoside or at least one (iii) vitamin B is present—for increasing or maintaining the body weight, for improving the ability to perform an activity of daily living of a mammal, for maintaining the ability to perform an activity of daily living of a mammal, or for reducing a deterioration in the ability to perform an activity of daily living of a mammal. | 11-19-2015 |
Martine Hori, Sagamihara-Shi JP
Patent application number | Description | Published |
---|---|---|
20130091944 | SYSTEMS AND METHODS OF DETERMINING PARAMETER VALUES IN A DOWNHOLE ENVIRONMENT - Systems and methods of determining parameter values in a downhole environment are described. An example method of determining a parameter value using calibration information is described. The calibration information corresponding to different parameter ranges in a downhole environment. The method includes determining a parameter range in the downhole environment using a controller and obtaining first calibration information or second calibration information based on the parameter range. The first calibration information associated with a first parameter range and the second calibration information associated with a second parameter range. The method also includes receiving an output signal from a sensor associated with the parameter and using the obtained calibration information to determine the parameter value based on the output signal received. | 04-18-2013 |
Martine Jandrot-Perrus, Vanes FR
Patent application number | Description | Published |
---|---|---|
20100261200 | Glycoprotein VI and Uses Thereof - The invention provides isolated nucleic acid molecules and polypeptide molecules that encode glycoprotein VI, a platelet membrane glycoprotein that is involved platelet-collagen interactions. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided. | 10-14-2010 |
Martine Jandrot-Perrus, Paris Cedex 18 FR
Patent application number | Description | Published |
---|---|---|
20100303724 | Polypeptides, Cyclic Polypeptides and Pharmaceutical Comprising Thereof for Non Invasive Specific Imaging of Fibrosis - The present invention relates to diagnostic imaging and in particular to the diagnostic imaging of fibrosis. More particularly, the present invention provides a polypeptides, cyclic polypeptides and pharmaceutical compositions suitable for the non-invasive visualization of fibrosis. The polypeptide of the invention may comprise an amino acid sequence consisting of: X1-X2-M-H-G-L-X7-L-X9-X10-D-E wherein amino acid X1 is R, F or P; amino acid X2 is F or V; amino acid X7 is Q, H or L; amino acid X9 is W or G and amino acid X10 is A or D. | 12-02-2010 |
Martine Jandrot-Perrus, Vanves FR
Patent application number | Description | Published |
---|---|---|
20110182899 | ANTI-GLYCOPTROTEIN VI SCFV FRAGMENT FOR TREATMENT OF THROMBOSIS - The present invention relates to a single chain variable fragment (scFv 9O12.2) directed against human glycoprotein VI, constituted of the VH and VL domains of 9 O12.2.2 monoclonal antibody linked via a (Gly | 07-28-2011 |
20130189259 | ANTI-GLYCOPROTEIN VI SCFV FRAGMENT FOR TREATMENT OF THROMBOSIS - The present invention relates to a single chain variable fragment (scFv 9O12.2) directed against human glycoprotein VI, constituted of the VH and VL domains of 9 O12.2.2 monoclonal antibody linked via a (Gly | 07-25-2013 |
Martine Jandrot-Perrus, Paris FR
Patent application number | Description | Published |
---|---|---|
20130310401 | METHOD AND KITS FOR DETERMINING PLATELET SUSCEPTIBILITY TO ACTIVATION IN A PATIENT - The invention relates to methods and kits for determining platelet susceptibility to activation in a patient. More particularly, the present invention relates to a method for determining platelet susceptibility to activation in a patient, comprising a step consisting of measuring the level of GPVI dimers at the platelet surface in a blood sample obtained from said patient. | 11-21-2013 |
Martine Jasson, Paris FR
Patent application number | Description | Published |
---|---|---|
20130149310 | COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME - The present invention provides compositions and methods of treating and improving the symptoms of rheumatoid arthritis using an antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). | 06-13-2013 |
20140302053 | COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME - The present invention provides compositions and methods of treating and improving the symptoms of rheumatoid arthritis using an antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R) with a DMARD. | 10-09-2014 |
Martine Larbanoix, Brussels BE
Patent application number | Description | Published |
---|---|---|
20110275693 | Pharmaceutical Compositions Comprising 2-Oxo-1-Pyrrolidine Derivatives - The present invention relates to an immediate release formulation of pharmaceutical compounds. | 11-10-2011 |
Martine Mansais, Marseille FR
Patent application number | Description | Published |
---|---|---|
20140037631 | ANTIGEN BINDING FORMATS FOR USE IN THERAPEUTIC TREATMENTS OR DIAGNOSTIC ASSAYS - The present invention relates to antigen binding formats for use in therapeutic treatments or diagnostic assays. The present invention relates to an antigen-binding format consisting of: a first fusion protein wherein the CH1 constant domain of an antibody is fused i) by its N-terminal end to the C-terminal end of a variable domain of an antibody and ii) by its C-terminal end to the N-terminal end of a variable domain of an antibody and, a second fusion protein wherein the CL constant domain of an antibody is fused by its N-terminal end to the C-terminal end of a variable domain of an antibody. | 02-06-2014 |
Martine Marigliano, Schiltigheim FR
Patent application number | Description | Published |
---|---|---|
20120190100 | ENZYMATIC COMPOSITION FOR THE DIGESTION OF CHICKEN EMBRYOS - The present invention relates to an enzymatic composition for the digestion of chicken embryos intended to the preparation of cells which are used for the production of viruses. The present invention also relates to a method for producing a wild type, an attenuated and/or a recombinant virus comprising a step of preparation of cells from chicken embryos using an enzymatic composition of the invention. The present invention relates to a purified wild type, attenuated and/or recombinant virus obtained and to a pharmaceutical composition, preferably a vaccine, comprising said virus for the treatment and/or the prevention a cancer, an infectious disease and/or an autoimmune disorder, and uses thereof. | 07-26-2012 |
Martine Maruani, Montreuil Juigne FR
Patent application number | Description | Published |
---|---|---|
20090131688 | METHOD FOR THE SYNTHESIS OF 4-BENZOFURAN-CARBOXYLIC ACID - The invention concerns a novel method for synthesis of 4-benzofuran-carboxylic acid or alkyl ester thereof. | 05-21-2009 |
Martine Mayne L'Hermite, Les Molieres FR
Patent application number | Description | Published |
---|---|---|
20100323207 | Growth of Carbon Nanotubes on Carbon or Metal Substrates - The invention relates to the growth of carbon nanotubes on a substrate, in particular a carbon or metal substrate on which the growth of such nanotubes is usually difficult. Accordingly, the invention includes a first phase that comprises depositing a ceramic sub-layer, followed by a second phase that comprises depositing carbon nanotubes on said sub-layer in a single step and in a single and same growth reactor. The growth can advantageously be carried out by chemical vapour deposition. | 12-23-2010 |
20110244585 | CHEMICAL SENSORS CONTAINING CARBON NANOTUBES, METHOD FOR MAKING SAME, AND USES THEROF - A device is disclosed for detecting at least one chemical compound comprising at least one carbon nanotube with several graphene layers, on which is grafted at least one molecule bearing group G1 capable of reacting with the chemical compound or a precursor of such a group G1. The uses and the method of making such a device is also disclosed. | 10-06-2011 |
20130108865 | MATERIAL INCLUDING NANOTUBES OR NANOWIRES GRAFTED IN A MATRIX, METHOD FOR PREPARING SAME AND USES THEREOF | 05-02-2013 |
Martine Miquel, Elancourt FR
Patent application number | Description | Published |
---|---|---|
20110189697 | RECOMBINANT CELLS AND PLANTS FOR SYNTHESIS OF VERY LONG CHAINS FATTY ACID (VLCFA) - The present disclosure is relative to a method for the production of Very-Long-Chain Fatty Acids (VLCFA) into a plant cell, including culturing a recombinant plant cell in an appropriate medium, wherein said plant cell is transformed with an heterologous gene encoding for an hydroxyacyl-CoA dehydratase. The disclosure is also relative to a method for producing vegetable oil including high levels of VLCFA. | 08-04-2011 |
Martine Naillon, Sceaux FR
Patent application number | Description | Published |
---|---|---|
20080215521 | METHOD FOR MONITORING A DECISION-MAKING PROCESS WHEN PURSUING AN OBJECTIVE IN ECONOMIC, TECHNICAL, AND ORGANIZATIONAL FIELDS - A method for controlling a decisional process when pursuing an aim in a specific application domain, such as economic, technical, and organizational fields. In the process, a system of agents is created, including creator cognitive agents of portable knowledge objects and constructor agents of knowledge objects by adding supplementary knowledge elements to the knowledge objects created. The system launches the decisional process by tracking the observation of an abnormality in the actual data of the application domain by the creation of an initial knowledge object representative of an alarm index and causes several decisional paths to be established linked to this object, under different points of view of different agents, each in its domain, and the decision is made following merging of decisional paths. | 09-04-2008 |
Martine Niejadlik, Los Altos, CA US
Patent application number | Description | Published |
---|---|---|
20110143711 | SYSTEMS AND METHODS TO SECURE TRANSACTIONS VIA MOBILE DEVICES - Systems and methods are provided to improve security of payment transactions via mobile communications. In one aspect, a system includes an interchange having a common format processor and a plurality of converters to interface with a plurality of different controllers of mobile communications. The converters are configured to communicate with the controllers in different formats and to communicate with the common format processor in a common format for the confirmation of payment requests, made via mobile phones. The common format processor is to determine a risk of a payment request being fraudulent based on the personal identification information associated with a mobile phone and, after the payment request is confirmed and when the risk is below a threshold, to communicate one or more premium messages to the mobile phone to collect funds to fulfill the payment request. | 06-16-2011 |
20110237222 | Systems and Methods to Provide Access Control via Mobile Phones - Systems and methods are provided to allow parental control via mobile communications. In one aspect, a system includes a data storage facility to store data associating a phone number with information indicative of an age of a user of the phone number; and an interchange coupled with the data storage facility. The interchange includes a common format processor and a plurality of converters to interface with a plurality of controllers. The converters are configured to communicate with the controllers in different formats and to communicate with the common format processor in a common format. The common format processor is to use one converter of the converters to communicate with a telephonic apparatus at the phone number to obtain parental consent, in response to a request from a third party website, such as a social networking website. | 09-29-2011 |
20120330823 | SYSTEMS AND METHODS TO PROVIDE ACCESS CONTROL VIA MOBILE PHONES - Systems and methods are provided to allow parental control via mobile communications. In one aspect, a system includes a data storage facility to store data associating a phone number with information indicative of an age of a user of the phone number; and an interchange coupled with the data storage facility. The interchange includes a common format processor and a plurality of converters to interface with a plurality of controllers. The converters are configured to communicate with the controllers in different formats and to communicate with the common format processor in a common format. The common format processor is to use one converter of the converters to communicate with a telephonic apparatus at the phone number to obtain parental consent, in response to a request from a third party website, such as a social networking website. | 12-27-2012 |
Martine Palous, Fontainebleau FR
Patent application number | Description | Published |
---|---|---|
20120276577 | Method for Determining the Susceptibility of a Cell Strain to Drugs - The present invention relates to a method for determining the susceptibility of a cell strain to a compound intended for controlling the growth of said cell strain, comprising: | 11-01-2012 |
Martine Parriche, Toulouse FR
Patent application number | Description | Published |
---|---|---|
20140127788 | TRANSFORMATION SYSTEM IN THE FIELD OF FILAMENTOUS FUNGAL HOSTS - A novel transformation system in the field of filamentous fungal hosts for expressing and secreting heterologous proteins or polypeptides is described. The invention also covers a process for producing large amounts of polypeptide or protein in an economical manner. The system comprises a transformed or transfected fungal strain of the genus | 05-08-2014 |
Martine Perichon, Chelles FR
Patent application number | Description | Published |
---|---|---|
20100063139 | USE IN A COSMETIC COMPOSITION OF LIPOCHROMAN-6 TO ENHANCE THE RADIANCE OF THE COMPLEXION OF THE SKIN, ESPECIALLY THE SKIN OF THE FACE - The invention relates to the use, in a cosmetic composition intended for topical application to the skin, of lipochroman-6 as an active intended to enhance and/or restore the radiance of the complexion of the skin, especially the skin of the face. | 03-11-2010 |
Martine Perree-Fauvet, Villebon Sur Yvette FR
Patent application number | Description | Published |
---|---|---|
20090314660 | Novel Electropolymerisable Monomers, Soluble in an Aqueous Solution and Comprising a Metalloporphyrin - The invention relates to novel electropolymerisable monomers which are to be polymerised in an aqueous solution and comprise: an electropolymerisable pattern selected from acetylene, pyrrols, thiophenes, indols, anilines, azines, p-phenylene vinylenes, p-phenylenes, pyrenes, furanes, selenophenes, pyrridazines, carbazoles, acrylates, methacrylates and the derivatives thereof, and a metalloporphyrine which is substituted by at least two ionised or ionisable entities in an aqueous solution. The invention also relates to a method for the polymerisation of such monomers, to the electroactive probe that can be obtained by the polymerisation of such monomers, and to a method for detecting a target ligand in a biological sample using one such electroactive probe. | 12-24-2009 |
Martine Piccart, Brussels BE
Patent application number | Description | Published |
---|---|---|
20080275652 | GENE-BASED ALGORITHMIC CANCER PROGNOSIS - Gene-Based Algorithmic Cancer Prognosis relates to methods and systems for prognosis determination in tumor samples. The methods and systems measure gene expression in a tumor sample and applying a gene-expression grade index (GGI) or a relapse score (RS) to yield a number c risk score. | 11-06-2008 |
20090186078 | TREATMENT OF TRIPLE RECEPTOR NEGATIVE BREAST CANCER - The present invention relates to the use of a liposomal preparation for the manufacture of a pharmaceutical composition and the use of such a composition for the treatment of ‘triple receptor negative’ breast cancer. | 07-23-2009 |
20120071346 | GENE-BASED ALGORITHMIC CANCER PROGNOSIS - The present invention is related to the methods and systems for prognosis determination in tumor samples, by measuring gene expression in a tumor sample and applying a gene-expression grade index (GGI) or a relapse score (RS) to yield a number c risk score. | 03-22-2012 |
20120183604 | Treatment of Triple Receptor Negative Breast Cancer - The present invention relates to the use of a liposomal preparation for the manufacture of a pharmaceutical composition and the use of such a composition for the treatment of “triple receptor negative” breast cancer. | 07-19-2012 |
Martine Poffet, Berne CH
Patent application number | Description | Published |
---|---|---|
20140209544 | REMINERALIZATION OF DESALINATED AND OF FRESH WATER BY DOSING OF A CALCIUM CARBONATE SOLUTION IN SOFT WATER - The present invention concerns a process for treating water and the use of calcium carbonate in such a process. In particular, the present invention is directed to a process for remineralization of water comprising the steps of providing feed water, providing an aqueous solution of calcium carbonate, wherein the aqueous solution of calcium carbonate comprises dissolved calcium carbonate and reaction species thereof, and combining the feed water and the aqueous calcium carbonate solution. | 07-31-2014 |
20140360940 | PROCESS FOR THE PREPARATION OF AN AQUEOUS SOLUTION COMPRISING AT LEAST ONE EARTH ALKALI HYDROGEN CARBONATE AND ITS USE - The present invention refers to a process for the preparation of an aqueous solution comprising at least one earth alkali hydrogen carbonate and its uses. The process is carried out in a reactor system that comprises a tank ( | 12-11-2014 |
Martine Poffet, Uettligen CH
Patent application number | Description | Published |
---|---|---|
20130164411 | MICRONIZED CaCO3 SLURRY INJECTION SYSTEM FOR THE REMINERALIZATION OF DESALINATED AND FRESH WATER - The present invention concerns a process for treating water and the use of calcium carbonate in such a process. In particular, the present invention is directed to a process for remineralization of water comprising the steps of providing feed water, and injecting gaseous carbon dioxide and a slurry into the feed water, wherein the slurry comprises micronized calcium carbonate. | 06-27-2013 |
20150037463 | MICRONIZED CaCO3 SLURRY INJECTION SYSTEM FOR THE REMINERALIZATION OF DESALINATED AND FRESH WATER - The present invention concerns a process for treating water and the use of calcium carbonate in such a process. In particular, the present invention is directed to a process for remineralization of water comprising the steps of (a) providing feed water having a concentration of carbon dioxide of at least 20 mg/l, preferably in a range of 25 to 100 mg/l, and more preferably in a range of 30 to 60 mg/l, (b) providing an aqueous slurry comprising micronized calcium carbonate, and (c) combining the feed water of step (a) and the aqueous slurry of step (b) in order to obtain remineralized water. | 02-05-2015 |
Martine Rothblatt, Silver Spring, MD US
Patent application number | Description | Published |
---|---|---|
20100076334 | ALZHEIMER'S COGNITIVE ENABLER - A computing device that enables user interaction when the user is in a mentally debilitating state includes a memory configured to store electroencephalogram (EEG) waveform signals. The EEG waveform signals are generated by associated recognition data. Response data is generated based on the associated recognition data and stored in memory. An input component is configured to receive an EEG waveform signal from a user. A processor is configured to compare the received EEG waveform signal with the stored EEG waveform signals to determine if the received EEG waveform signal matches a stored EEG waveform signal. An output component is configured to automatically output the response data generated by the associated recognition data based on the determination from the processor. | 03-25-2010 |
20140180159 | ALZHEIMER'S COGNITIVE ENABLER - A computing device that enables user interaction when the user is in a mentally debilitating state includes a memory configured to store electroencephalogram (EEG) waveform signals. The EEG waveform signals are generated by associated recognition data. Response data is generated based on the associated recognition data and stored in memory. An input component is configured to receive an EEG waveform signal from a user. A processor is configured to compare the received EEG waveform signal with the stored EEG waveform signals to determine if the received EEG waveform signal matches a stored EEG waveform signal. An output component is configured to automatically output the response data generated by the associated recognition data based on the determination from the processor. | 06-26-2014 |
20150262016 | COMPUTING DEVICE FOR ENHANCING COMMUNICATIONS - A computing device for enhancing communications is disclosed. The computing device includes a memory configured to store data, a video camera configured to receive video input data, and a microphone configured to receive audio input data. The computing device also includes a processor that is configured to analyze the received video input data, the received audio input data, and the data stored in the memory. The computing device further includes a visual display device that is configured to output a visual display based on the processor analysis, and a speaker output device that is configured to output an audio signal based on the processor analysis. | 09-17-2015 |
Martine Sainte-Marie, Nothalten FR
Patent application number | Description | Published |
---|---|---|
20120190100 | ENZYMATIC COMPOSITION FOR THE DIGESTION OF CHICKEN EMBRYOS - The present invention relates to an enzymatic composition for the digestion of chicken embryos intended to the preparation of cells which are used for the production of viruses. The present invention also relates to a method for producing a wild type, an attenuated and/or a recombinant virus comprising a step of preparation of cells from chicken embryos using an enzymatic composition of the invention. The present invention relates to a purified wild type, attenuated and/or recombinant virus obtained and to a pharmaceutical composition, preferably a vaccine, comprising said virus for the treatment and/or the prevention a cancer, an infectious disease and/or an autoimmune disorder, and uses thereof. | 07-26-2012 |
Martine Schroyen, Ames, IA US
Patent application number | Description | Published |
---|---|---|
20150216147 | GENETIC TEST AND GENETIC BASIS FOR SCID IN PIGS - The genetic basis for severe combined immunodeficiency disease (SCID) in pigs is described. In addition, tests for detecting pigs that are carriers for SCID or pigs with SCID are also described. Further, methods for producing pigs or herds of pigs with SCID are also described. Further, methods and compositions for treating, ameilioraing, inhibiting or correcting SCID are provided. | 08-06-2015 |
Martine Seno, St. Laurent Du Var FR
Patent application number | Description | Published |
---|---|---|
20120096034 | Method for automatically generating a text portion - Method for automatically generating a text portion applicable to a customer for at least one product, characterized in that it includes at a server side based on a plurality of data. According to the invention, rules data are processed so that a reduced rule is obtained and further used for generating the text portions with an engine dedicated to this task. | 04-19-2012 |
Martine Seu-Salerno, Neuilly-Sur-Seine FR
Patent application number | Description | Published |
---|---|---|
20130164354 | METHOD FOR THE EXTEMPORANEOUS PREPARATION OF COSMETIC COMPOSITIONS HAVING THE TEXTURE OF A CREAM AND COMPOSITIONS FOR CARRYING OUT SAID METHOD - Disclosed is a method for the preparation of cosmetic compositions having the texture of a cream. Said preparation is made at the time when the composition is used and includes bringing into contact with each other (A) a liquid phase, (B) a powder containing a gelling agent for the liquid phase (A), and (C) an active cosmetic ingredient, whereby the elements are brought into contact by adding phase (A) to phase (B), subjecting a solid powder containing phase (B) and phase (A) in an immobilized form to mechanical stress to release phase (A). Further disclosed are compositions comprising phase (B) and phase (A) in an immobilized form which are transformed into a cream when applied to the skin). | 06-27-2013 |
Martine Soete, Arras FR
Patent application number | Description | Published |
---|---|---|
20090053266 | Apicomplex vaccine strains of a family of sarcocystidae - The invention relates to attenuate mutated strains of apicomplex of a family of Sarcocystidae, containing inactivated MIC | 02-26-2009 |
Martine Stihle, Michelbach-Le-Bas FR
Patent application number | Description | Published |
---|---|---|
20100323427 | INSULIN DEGRADING ENZYME CRYSTALS - The present invention provides apo crystals and co-crystals of insulin-degrading enzyme (IDE) and their uses in drug development. | 12-23-2010 |
20110060580 | LXR LIGAND BINDING DOMAIN (LXR LBD) CRYSTALS - The present invention relates to co-crystals of Liver X receptor beta ligand binding domain (LXRβ-LBD) with agonists and to the three-dimensional X-ray crystal structures derived thereof. | 03-10-2011 |
Martine Tellwright, Barnham GB
Patent application number | Description | Published |
---|---|---|
20110173730 | NEMESIA plant named 'FLEURBW' - A new and distinct cultivar of | 07-14-2011 |
Martine Vernhet, Montpellier FR
Patent application number | Description | Published |
---|---|---|
20100041709 | SUBSTITUTED N-(4-CYANO-1H-PYRAZOL-3-YL)METHYLAMINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF - The present invention relates to compounds corresponding to formula (I): | 02-18-2010 |
Martine Villatte, Rueil Malmaison FR
Patent application number | Description | Published |
---|---|---|
20120085261 | CERAMIC PARTICLES AND COATING COMPOSITIONS INCLUDING SAID PARTICLES - The present invention relates to coating compositions for metallic devices, especially for aircrafts, to provide protection against corrosion. The coating composition comprises ceramic particles having at least one active material substantially homogeneously distributed throughout each particle. The active material being releasable in the presence of a liquid by solubilization into the liquid. | 04-12-2012 |
20130101800 | MULTIFUNCTIONAL COATING FOR AIRCRAFT - A method for coating a surface comprises applying a layer of coating composition onto the surface, mechanically forming parallel ribs on the layer, and simultaneously polymerizing the layer with ultraviolet radiations. The coating composition comprises a mass percentage of urethan-acrylate oligomer, with an average molar mass in number between 1000 and 5000 g·mol | 04-25-2013 |
Martine Whissel, Ottawa CA
Patent application number | Description | Published |
---|---|---|
20100041100 | FAMILY 6 CELLULASE WITH DECREASED INACTIVATION BY LIGNIN - A modified | 02-18-2010 |
20100093040 | MODIFIED BETA-GLUCOSIDASES WITH IMPROVED STABILITY - Provided are modified beta-glucosidase enzymes, derived from the | 04-15-2010 |